Vita Laboratories filed complaints with the Market Court about the procurements because they had not been put out to tender.
The Market Court has ruled on two appeals lodged by Vita Laboratories concerning the procurement of the Helsinki and Uusimaa Hospital Districts.
In the spring and September of last year, Hus signed agreements to order corona tests from Synlab laboratories. According to the procurement decision, the estimated value of the contract is approximately EUR 100 million, on top of which there will be other operating costs.
Vita Laboratories filed complaints with the Market Court about the procurements because they had not been put out to tender. Hus procured corona tests for border control on behalf of the Ministry of Social Affairs and Health.
The Market Court agreed with Hus’ view that there was an urgent and unpredictable need for direct procurement. Hus had also left an option in the contract to buy more tests, but there are no legal grounds for that.
Yle’s MOT program recently linked test stores to Hus’s previous competition clashes, for which Hus received fines from the Consumer and Competition Agency. CEO of Hus Juha Tuominen told IS at the time that this was a different matter.
He also said there was no time to tender for procurement and the amount needed would not have been obtained elsewhere fast enough as infections increased at the same time.
Read more: State aid of up to EUR 200 million for HUS’s Synlab agreement – criticism from a competitor
Source site www.is.fi